CAMP4 Therapeutics

We’re pleased to announce that the first participant has been dosed in the Phase 1 clinical study of CMP-CPS-001, our first-in-class therapeutic for the potential treatment of urea cycle disorders (UCDs). Occurring across all ages from infants to adults, UCDs are a group of severe, rare, inherited metabolic diseases impacting protein metabolism. They can cause irreversible brain damage, disability, seizures, and may be fatal.     The advancement of our lead program highlights the power of our RAP Platform™ to upregulate gene expression using programmable, targeted medicines, with CMP-CPS-001 moving from screen-to-clinic within 3 years. 📢 Learn more about the study: https://bit.ly/4csWzeA #clinicaltrials #clinicalresearch #ureacycledisorders #raredisease #biotechnology 

ICYMI: CEO Josh Mandel-Brehm shares the path of his biotech career, from having scientific discussions around the dinner table as a child, through the ascent of CAMP4 – leading to the recent initiation of the first clinical trial of our lead mRNA-amplifying therapy. ▶️ Listen to the episode of Alix Ventures’ BIOS podcast: https://bit.ly/4arFcZm #podcast #mRNA #geneticdisease #biotech

Don’t miss CEO Josh Mandel-Brehm discussing the recently launched clinical study of our candidate for the potential treatment of urea cycle disorders on Vial's First in Human podcast.    🎧Listen at: https://lnkd.in/eifn3VRS #biotech #raredisease #clinicalresearch

CAMP4 recently became a clinical-stage company with the start of our Phase 1 clinical study of CMP-CPS-001, a potential therapeutic for the treatment of urea cycle disorders (UCDs). This Clinical Trials Day, we are incredibly grateful for everyone who contributes to bringing innovative medicines to patients. #ClinicalTrialsDay #CTD2024

Next week, CAMP4 VP of Platform Alla Sigova will present on our unique approach to amplifying RNA at the American Society of Gene & Cell Therapy’s 27th Annual Meeting. She’ll walk through how we applied our RAP Platform™ to develop our clinical candidate, CMP-CPS-001, for the potential treatment of urea cycle disorders. Mark your calendar: https://bit.ly/3UDBKX5 #ASGCT2024 #ASGCT #RNA #ureacycledisorders

Thanks to Alix Ventures for this candid, in-depth video interview with CAMP4 CEO Josh Mandel-Brehm!  Hear the stories behind our company’s beginnings, name evolution, scientific discoveries, and everything in between leading to our recent clinical milestone: https://lnkd.in/gkr8Da-3 #biotechnology #mRNA #innovation

At #RECOMB2024? Don’t miss this afternoon’s poster session, where CAMP4 Senior Data Scientist Guanjue Xiang will present on JMnorm, our proprietary computational tool that can simultaneously normalize multiple epigenomic features across datasets. 🖥️ More on JMnorm: https://bit.ly/4dbFpm3 #genomics #AI #bioinformatics #opensource

Happy #DNADay24! As a proud part of the genomics research community, CAMP4 is inspired by new findings and insights about our genomes, the role RNA plays in our bodies and in disease, and the potential of genetic medicines. Today and every day, we celebrate the latest advances and explore ways we can make a positive impact on patients’ lives. https://bit.ly/44279Fx

Our Campers kicked off 2024 by hitting milestones…and the slopes! In the last few months, we’ve celebrated winter holidays, enjoyed a ski trip, and competed in an inaugural ping pong tournament. We appreciate having a team that can do both!

Next week, CAMP4 CEO Josh Mandel-Brehm will join an expert panel at USAIC's 18th Annual BioPharma & Healthcare Summit to discuss new approaches for rare and neurological diseases. Find the agenda here: https://bit.ly/3VYAkay #USAIC24 #LifeSciences #RareDisease #Neuroscience